FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.
Barbato MI, Bradford D, Ren Y, Aungst SL, Miller CP, Pan L, Zirkelbach JF, Li Y, Bi Y, Fan J, Grimstein M, Dorff SE, Amatya AK, Mishra-Kalyani PS, Scepura B, Schotland P, Udoka O, Ojofeitimi I, Leighton JK, Rahman NA, Pazdur R, Singh H, Kluetz PG, Drezner N.
Barbato MI, et al. Among authors: amatya ak.
Clin Cancer Res. 2024 Aug 15;30(16):3364-3370. doi: 10.1158/1078-0432.CCR-24-0949.
Clin Cancer Res. 2024.
PMID: 38875108
Clinical Trial.